Recently, Gan & Lee Pharmaceuticals (stock code: 603087.SH) announced that its Aspart Insulin 30 Injection has officially obtained import marketing authorization from the Central Drugs Standard Control Organisation (CDSCO) of India, becoming the first approved biosimilar of Aspart Insulin 30 Injection in India.

Breaking the monopoly of original research drugs and solving the problem of accessibility to diabetes diagnosis and treatment in India.
India has one of the largest diabetes populations in the world. According to the latest data from the International Diabetes Federation (IDF), there are approximately 89.83 million people aged 20-79 with diabetes in India, a number projected to rise to 157 million by 2050, representing a growth rate of 75% .¹ With the continued growth of the local diabetes population, the market demand for high-quality, readily available insulin products is increasingly urgent. However, the supply of aspart insulin 30 injection in India has long relied on a few original drug manufacturers, and patients still face challenges in terms of drug accessibility and treatment costs.

The approval of Gan & Lee Pharmaceuticals' product, relying on the company's mature large-scale production system, stable supply chain guarantee, and partners' localized commercial channels in India, will break the long-standing monopoly of foreign original research companies in the local market for this product, enhance the coverage of high-quality insulin products in primary healthcare institutions, provide local patients with long-term, stable and more affordable treatment options, and help improve the level of standardized diabetes treatment in India.

Implementing a dual-track approach to build core competitiveness in the South Asian market
India is a crucial foothold for Gan & Lee Pharmaceuticals in its deep cultivation of the South Asian market. The company adheres to a dual strategy of "deepening the market with mature products and forward-looking layout of innovative pipelines," continuously improving its product portfolio in the Indian market.

In the mature insulin field, Gan & Lee Pharmaceuticals has implemented a tiered product introduction strategy tailored to the characteristics of clinical treatment in India. It has successively launched glargine insulin cartridges and pre-filled injection pens, balancing the needs for basic treatment supply with convenient administration. These two dosage forms synergistically cover different medication scenarios, driving the company's glargine insulin products to maintain a top-three market position in India for over a decade. The approval of this aspart insulin 30 injection expands the company's product portfolio in India from long-acting basal insulin to premixed insulin, further enriching its core diabetes treatment product portfolio and building a diversified, multi-scenario hypoglycemic product supply system.

While consolidating its position in the mature insulin product market, the company is also proactively expanding into the innovative drug sector. In December 2025, Gan & Lee Pharmaceuticals reached an exclusive licensing and supply agreement with a leading Indian pharmaceutical company for Bovangrautide (GZR18), authorizing it to conduct local clinical development and commercialization of the product in India.

As a result, Gan & Lee Pharmaceuticals has established a mature layout in the Indian market that combines generic and innovative drugs with a dual-track approach, continuously enhancing its core competitiveness and becoming a benchmark for Chinese pharmaceutical companies to cultivate the South Asian biopharmaceutical market.

In recent years, Gan & Lee Pharmaceuticals has continuously advanced its globalization strategy, moving from "product export" to "ecosystem co-construction." Its core insulin products have achieved breakthroughs in several key markets, including Europe, the Middle East, Latin America, and Asia, repeatedly breaking the monopolies of foreign giants. Looking ahead, the company will continue to accelerate overseas registration and commercialization, deepen strategic cooperation with India and South Asia, and expand its product portfolio for diabetes and metabolic disease treatments, leveraging its product strength and innovative R&D capabilities to contribute to the global treatment of chronic diseases.

https://bydrug.pharmcube.com/news/detail/eb670a82b56939eb7cc2133f7bb81b5e